Whitehawk Therapeutics (WHWK) Restructuring Costs (2019 - 2024)
Whitehawk Therapeutics (WHWK) posted quarterly Restructuring Costs of $2.6 million for Q3 2024, up 6897.22% quarter-over-quarter from -$38810.0 in Q3 2019.
Whitehawk Therapeutics (WHWK) Restructuring Costs (2019 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Restructuring Costs for 2 consecutive years, with $2.6 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Restructuring Costs changed N/A year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (changed 0.0% YoY), while the FY2024 annual figure was $2.6 million, changed N/A from the prior year.
- Restructuring Costs climbed to $2.6 million in Q3 2024 per WHWK's latest filing, from -$38810.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $2.6 million in Q3 2024 and bottomed at $2.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.64 Mn |
| Sep 30, 2019 | -38,810.00 |